Literature DB >> 9563134

[Development of tumor selection based on pathological stage in clinically localized prostate carcinoma].

J Noldus1, M Graefen, P Hammerer, R P Henke, H Huland.   

Abstract

Four hundred and eighty-eight radical retropubic prostatectomies (RRP) were performed on clinically localized prostate cancer at one institution within 5 years (1992-1996). These were then analyzed regarding the migration of pathological tumor stages towards more localized stages. Within the observation period, the annual rate of RRP increased by 81% from 69 to 125 cases. The authors noted a decline in the occurrence of advanced tumor stages (65.0% to 39.2%) and small cancers (< 0.5 cc: 7.2% to 1.6%) and an increase in pathological T2 tumors (30.4% to 55.2%). The rate of positive surgical margins declined from 34.7% to 12.8% (for all pathological stages). These data confirm trends which were observed in the USA with increasing detection and treatment of localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563134     DOI: 10.1007/s001200050173

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  3 in total

1.  Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer.

Authors:  Felix K-H Chun; Markus Graefen; Mario Zacharias; Alexander Haese; Thomas Steuber; Thorsten Schlomm; Jochen Walz; Pierre I Karakiewicz; Hartwig Huland
Journal:  World J Urol       Date:  2006-02-28       Impact factor: 4.226

2.  Impact of preoperative antiandrogen medication and nerve-sparing surgery on the outcome of radical prostatectomy.

Authors:  J Hodzic; P Jedrusik; T Reckwitz; H-J Knopf; K Golka
Journal:  Int Urol Nephrol       Date:  2008-04-10       Impact factor: 2.370

Review 3.  [Advantages of nerve-sparing pelvic surgery. Animal experiments and clinical results].

Authors:  A Stenzl; A G Anastasiadis; S Corvin; G Feil; H Strasser; M Kuczyk
Journal:  Urologe A       Date:  2004-02       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.